These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10301497)

  • 1. Some observations on the collection of medical event data.
    Mohberg NR
    Drug Inf J; 1987; 21(1):55-62. PubMed ID: 10301497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.
    O'Neill RT
    Drug Inf J; 1987; 21(1):9-20. PubMed ID: 10281640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data on drugs and adverse experiences: moving from the specific to the general.
    Windhorst DB; Pun EF; Zubkoff LA
    Drug Inf J; 1987; 21(1):39-46. PubMed ID: 10301495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for post-marketing screening of adverse reactions to drugs: initial results.
    Knapp DE; Zax BB; Rossi AC; O'Neill RT
    Drug Intell Clin Pharm; 1980 Jan; 14(1):23-7. PubMed ID: 10245773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of adverse drug reactions in clinical trials.
    Petrie WM; Levine J
    Int Pharmacopsychiatry; 1978; 13(4):209-16. PubMed ID: 730486
    [No Abstract]   [Full Text] [Related]  

  • 7. A prescription for monitoring drugs.
    Marshall E
    Science; 1980 Feb; 207(4433):853-5. PubMed ID: 7355265
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse drug events: identification and attribution.
    Rogers AS
    Drug Intell Clin Pharm; 1987 Nov; 21(11):915-20. PubMed ID: 3678067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building data quality into clinical trials.
    Crerand WJ; Lamb J; Rulon V; Karal B; Mardekian J
    J AHIMA; 2002; 73(10):44-6, 48-53, 2; quiz 55-6. PubMed ID: 12432815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ensuring data quality in the pharmaceutical industry.
    Collins CM
    J AHIMA; 1998 Jun; 69(6):34-9. PubMed ID: 10180097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panel 3: phase III investigations.
    Azarnoff DL; Abrams WB; Cuttner J; Hewitt WL; Hailman HF
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):650-2. PubMed ID: 1102242
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal.
    Crépin S; Villeneuve C; Merle L
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):719-24. PubMed ID: 26887649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency.
    Davidson SE; Trotti A; Ataman OU; Seong J; Lau FN; da Motta NW; Jeremic B
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1218-21. PubMed ID: 17689027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.
    Cato A
    Drug Inf J; 1987; 21(1):3-7. PubMed ID: 10281637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, monitoring, and analysis issues relative to adverse events.
    Peace KE
    Drug Inf J; 1987; 21(1):21-8. PubMed ID: 10301494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey.
    Loke YK; Derry S
    BMC Clin Pharmacol; 2001; 1():3. PubMed ID: 11591227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA introductory comments: clinical studies design and evaluation issues.
    Woodcock J
    Clin Trials; 2005; 2(4):273-5. PubMed ID: 16281424
    [No Abstract]   [Full Text] [Related]  

  • 18. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 19. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.